DC Field | Value | Language |
---|---|---|
dc.contributor.author | Min Young Lee | - |
dc.contributor.author | Ki Hoan Nam | - |
dc.contributor.author | K C Choi | - |
dc.date.accessioned | 2017-04-19T10:18:52Z | - |
dc.date.available | 2017-04-19T10:18:52Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1976-9148 | - |
dc.identifier.uri | 10.4062/biomolther.2015.149 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/13183 | - |
dc.description.abstract | In Drosophila, rhomboid proteases are active cardinal regulators of epidermal growth factor receptor (EGFR) signaling pathway. iRhom1 and iRhom2, which are inactive homologs of rhomboid intramembrane serine proteases, are lacking essential catalytic residues. These are necessary for maturation and traffickingof tumor necrosis factor-alpha (TNF-α) converting enzyme (TACE) from endoplasmic reticulum (ER) to plasma membrane through Golgi, and associated with the fates of various ligands for EGFR. Recent studies have clarifiedthat the activation or downregulation of EGFR signaling pathways by alteration of iRhoms are connected to several human diseases including tylosis with esophageal cancer (TOC) which is the autosomal dominant syndrom, breast cancer, and Alzheimer’s disease. Thus, this review focuses on our understanding of iRhoms and the involved mechanisms in the cellular processes. | - |
dc.publisher | Korea Soc-Assoc-Inst | - |
dc.title | iRhoms : Its functions and essential roles | - |
dc.title.alternative | iRhoms : Its functions and essential roles | - |
dc.type | Article | - |
dc.citation.title | Biomolecules & Therapeutics | - |
dc.citation.number | 2 | - |
dc.citation.endPage | 114 | - |
dc.citation.startPage | 109 | - |
dc.citation.volume | 24 | - |
dc.contributor.affiliatedAuthor | Min Young Lee | - |
dc.contributor.affiliatedAuthor | Ki Hoan Nam | - |
dc.contributor.alternativeName | 이민영 | - |
dc.contributor.alternativeName | 남기환 | - |
dc.contributor.alternativeName | 최경철 | - |
dc.identifier.bibliographicCitation | Biomolecules & Therapeutics, vol. 24, no. 2, pp. 109-114 | - |
dc.identifier.doi | 10.4062/biomolther.2015.149 | - |
dc.subject.keyword | EGFR | - |
dc.subject.keyword | IRhom1 | - |
dc.subject.keyword | IRhom2 | - |
dc.subject.keyword | TACE | - |
dc.subject.keyword | TNF-α | - |
dc.subject.local | EGFR | - |
dc.subject.local | IRhom1 | - |
dc.subject.local | IRhom2 | - |
dc.subject.local | TACE | - |
dc.subject.local | Tumor necrosis fa tor-α | - |
dc.subject.local | TNFα | - |
dc.subject.local | Tumor necrosis factor (TNF)-α | - |
dc.subject.local | Tnf-α | - |
dc.subject.local | TNF-a | - |
dc.subject.local | TNF-alpha | - |
dc.subject.local | Tumor necrosis factor-α | - |
dc.subject.local | tumor necrosis factor-alpha | - |
dc.subject.local | TNFa | - |
dc.subject.local | Tumor necrosis factor alpha | - |
dc.subject.local | Tumor necrosis factor-alpha | - |
dc.subject.local | TNF-α | - |
dc.subject.local | tumor necrosis factor-α | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.